Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fisher, R. I.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fisher, R. I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 7:S131-S133, 1996
© 1996 European Society for Medical Oncology

Symposium Article

Report of Workshop 5: Early high-dose chemotherapy

R. I. Fisher

Division of Hematology/Oncology, Loyola University Stritch School of Medicine Maywood, IL, U.S.A.

Correspondence to: Richard I. Fisher, MD. Director Oncology Institute Loyola University Cancer Center Maywood IL 60153 U.S.A.

Workshop 5, entitled ‘Early High-Dose Chemotherapy for Hodgkin's Lymphoma’, was conducted at the Third International Symposium on Hodgkin's Lymphoma in Köln, Germany, on September 23, 1995. The objective of the workshop was to determine whether one could identify, at diagnosis, a high-risk group of Hodgkin's disease patients who could be subjected to high-dose therapy with acceptable toxicity as part of their initial therapy. D. Hasenclever of Leipzig, Germany, presented a preliminary analysis of a multivariate model which involved over 4000 patients with advanced Hodgkin's disease. Unfortunately, the model did not permit the definition of a significant group of patients with less than a 50% progression free surviva1 at 5 years. A. Carella from Genoa, Italy, and S. J. Proctor from Newcastleupon-Tyne, U.K., presented their ongoing randomized trials of early high-dose therapy while N. Schmitz from Kiel, Germany, presented the results of a matched pair analysis of patients receiving high-dose chemotherapy compared to patients receiving conventional chemotherapy. A. H. Goldstone from London, United Kingdom, and J. O. Armitage from Omaha, U.S.A., presented important long-term toxicity data. C. Gisselbrecht from Paris, France, presented the data on second neoplasms. D. L. Longo from Frederick, U.S.A., focused on the results of using either conventional or high- dose therapy as salvage therapy. In summary the workshop defined both the enthusiasm for improving the treatment results of patients with advanced Hodgkin's disease by using high-dose therapy and the problems associated with conducting those type of studies.

high-dose chemotherapy, Hodgkin's disease, prognostic factors, toxicity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.